A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.

Peng GuXu ChenRuihui XieWeibin XieLi HuangWen DongJinli HanXiaodong LiuJihong ShenJian HuangTianxin Lin

Published in: Molecular cancer (2019)

Lnc-LBCS functions as a novel AR translational regulator that suppresses castration resistance of prostate cancer by interacting with hnRNPK. This sheds a new insight into the regulation of CRPC by lncRNA mediated AR activation and LBCS-hnRNPK-AR axis provides a promising approach to the treatment of CRPC.

Keyphrases

prostate cancer
radical prostatectomy
transcription factor
smoking cessation
replacement therapy